Ferric carboxymaltose significantly increased hypophosphataemia risk in IBD patients with IDA

A new study published in BMJ Gut found that, iron deficiency anaemia (IDA) treatment with ferric derisomaltose (FDI) and ferric carboxymaltose (FCM) was equally effective, while the latter dramatically increased the rate of hypophosphataemia.

Hypophosphataemia can be brought on by intravenous iron, a typical treatment for anaemia and iron shortage brought on by inflammatory bowel disease. In this study, the incidence of hypophosphataemia following ferric derisomaltose or ferric carbo therapy was studied.

20 outpatient hospital clinics throughout Europe participated in this randomised, double-blind clinical investigation (Austria, Denmark, Germany, Sweden, UK). Using the same haemoglobin- and weight-based dosage regimens, adults with IBD and IDA were randomly assigned 1:1 to receive FCM or FDI at baseline and at Day 35. The main result was the frequency of hypophosphataemia (serum phosphate 2.0 mg/dL) in the safety analysis set (all patients who received 1 dosage of study medication) at any point from baseline to Day 35. Measurements were made of patient-reported fatigue scores as well as indicators of mineral and bone homeostasis.